TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)
September 29, 2022 13:00 ET
|
TearClear Corp.
Successfully met the primary and all secondary endpoints On track for New Drug Application (NDA) filing, with the FDA in Q1 2023 TC-002 is the first of four proprietary glaucoma drugs in the...
TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial
February 07, 2022 05:00 ET
|
TearClear Corp.
BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- TearClear, a late clinical stage ophthalmic pharmaceutical company, is pleased to announce the TC-002 Phase 3 trial has been successfully initiated....
TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%
September 08, 2021 09:52 ET
|
TearClear Corp.
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- TearClear, a late clinical stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational...
TearClear Moving Toward Clinical Trials and Strengthening Leadership Team
March 16, 2021 07:28 ET
|
TearClear Corp.
BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- TearClear continues to make progress on the development of its first-in-class platform of preservative-free topical medications. With a successful Pre-IND...
TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma
December 01, 2020 06:00 ET
|
TearClear Corp.
BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- TearClear, an emerging ophthalmic pharmaceutical company, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S....
TearClear Appoints Robert Bailey to Board of Directors
September 29, 2020 06:00 ET
|
TearClear Corp.
BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- TearClear announces the appointment of industry veteran Robert Bailey to the company’s Board of Directors. Mr. Bailey brings over two decades of leadership...
TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development
August 11, 2020 07:00 ET
|
TearClear Corp.
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- TearClear has raised $22M in a Series B funding round. The investment will be used to advance multiple clinical programs in development, with two lead...
TearClear appoints Dr. Amir Shojaei Chief Development Officer
May 20, 2020 07:00 ET
|
TearClear Corp.
BOSTON, May 20, 2020 (GLOBE NEWSWIRE) -- TearClear Corp., an emerging Ophthalmic Pharmaceutical Company, has announced the appointment of Amir Shojaei, Pharm.D., Ph.D., as Chief Development Officer,...
TearClear appoints Robert J. Dempsey Chief Executive Officer
April 16, 2020 07:30 ET
|
TearClear Corp.
BOSTON, April 16, 2020 (GLOBE NEWSWIRE) -- TearClear, a global Ophthalmic Pharmaceutical Company, today announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the...
TearClear Appoints Chief Scientific and Innovation Officer
May 29, 2019 08:00 ET
|
TearClear Corp.
Industry Leader Srini Venkatesh, PhD, to drive TearClear’s scientific and R&D strategy Supports the next phase of development for its disruptive ophthalmic pharmaceutical platform ORANGE...